HIV INFECTIONS

This early-stage study tests a new HIV vaccine booster called VRIPRO in 40 healthy adults aged 18 to 60 who previously received an HIV vaccine in the HVTN 706 trial. Participants will get three shots over 24 weeks. The main goals are to check for side effects and measure the immu…

This early-stage study tests three experimental mRNA vaccines designed to train the immune system to fight HIV. About 96 healthy adults without HIV in South Africa will receive either the vaccine or a placebo. The main goals are to check safety and see if the vaccines trigger str…

This study tests whether smartphone tools can help people with HIV achieve and maintain viral suppression (low virus levels). It enrolls 1,000 adults who face challenges like substance use, mental health issues, or barriers to care. Participants use their phones to track adherenc…

This study compares two ways to offer cervical cancer screening to women living with HIV: standard clinic-based screening versus adding community outreach where women receive HPV self-collection kits at home or other community spots. About 7,600 women will take part across multip…

This study tests whether a program led by peers—combining acceptance and commitment therapy, exercise, and social support—can help women living with HIV take their medication more consistently. About 300 women who have HIV, use substances, and have experienced violence will take …

This early-stage study is testing a new long-acting injectable drug called VH4524184 in 268 healthy adults. The goal is to see if it is safe and how the body processes it, as a potential new treatment for HIV. Participants receive either the drug or a placebo, and researchers mon…

This study looks at whether giving long-acting injectable HIV medication and birth control (like implants or shots) together is safe and works well for adolescent girls and young women living with HIV in Kenya. About 700 participants aged 15-24 will either get the long-acting HIV…

This study tests whether a team-based program called ARTAS can help people with HIV stay connected to care after they leave the hospital. Researchers will enroll 250 adults who are newly diagnosed or not currently in HIV care. The goal is to see if this approach improves follow-u…

This study tests if a long-acting injectable HIV medication (CAB LA + RPV LA) can suppress the virus better than daily pills in people who still have detectable HIV despite oral treatment. About 332 participants will receive either the injections or continue standard oral therapy…

This study is testing a mobile app called WiseApp along with a smart pill dispenser to help Spanish-speaking people with HIV take their medication consistently. The study will include 248 participants from New York City and the Dominican Republic and will track medication adheren…

This study tests the safety and how the body handles the drug cabotegravir in newborns (up to 10 days old) who were exposed to HIV-1. About 44 healthy babies born at full term and weighing at least 2 kg will receive the drug either by mouth or injection. The goal is to find safe …

This study tests whether same-day HPV testing and treatment can help prevent cervical cancer in 600 women living with HIV in the Dominican Republic. Cervical cancer is a leading cause of death in these women, but it is preventable with early detection. The goal is to see if this …

This study tests whether training traditional healers to provide HIV counseling, testing, and medication support can help more people in rural Uganda achieve viral suppression. 650 adults with HIV will receive either standard clinic care alone or standard care plus support from a…

This study tests whether a mobile app called Positive Peers can help young people (ages 13-34) with HIV keep the virus under control. Participants use the app and complete surveys over 12 months. The goal is to see if app use leads to viral suppression and better care retention.

This study tests a program called Kisoboka for men living with HIV who drink heavily in fishing communities. The goal is to help them drink less, take their HIV medication as prescribed, and achieve undetectable viral loads. About 716 men will be randomly assigned to different le…

This study tests whether a combination of lab-made antibodies and a therapeutic vaccine can help people with HIV control the virus without daily antiretroviral therapy. About 48 adults who started HIV treatment very early (during acute infection) will receive the antibodies and v…

This study in Botswana tests whether a combination of three lab-made antibodies can keep HIV under control in children who started treatment early. About 41 kids aged 2 to 12 will receive the antibodies while pausing their regular HIV pills. The goal is to see if the antibodies a…

This study tests whether trained peer supporters can help Black individuals living with or at high risk for HIV stay on track with long-acting injectable HIV medication (PrEP/ART) and reduce substance use. About 186 participants will receive either peer-delivered problem-solving …

This study tests a new treatment for people with HIV that uses their own immune cells, modified in a lab to better recognize and attack the virus. About 18 participants will receive an infusion of these special cells, and then temporarily stop their HIV medications to see if the …

This study tests whether providing medically tailored meals along with intensive lifestyle coaching helps adults with HIV and type 2 diabetes (or high risk for it) lose weight and control blood sugar better than meals alone. About 200 participants will be followed for 18 months. …

This study tests a new program called QUIT-AD that combines existing methods to help people with HIV or TB quit smoking. The program will be offered to 86 adults in Cape Town, South Africa who smoke daily. Researchers will check if the program is practical, well-liked, and helps …

This study tests a new oral drug, VH4524184, taken with two standard HIV medicines (emtricitabine and tenofovir alafenamide) in 150 adults with HIV-1 who have never received treatment. The goal is to see if the new combination can suppress the virus as well as a current standard …

This study looks at people in Uganda and South Africa whose HIV medication (TLD) is no longer working well. Researchers will test different strategies to get the virus under control again. The goal is to find the best way to help these patients achieve undetectable viral levels.

This study tests whether bempedoic acid, a cholesterol-lowering drug, can reduce artery inflammation and improve heart health in people with HIV who are on effective treatment. About 121 adults aged 40 and older with controlled HIV and at least one heart risk factor will receive …

This early-stage study is testing a new long-acting injectable drug, VH4011499, to see if it is safe and tolerable for preventing HIV. About 168 healthy adults without HIV will receive one or more doses as a shot under the skin or into a muscle. Researchers will monitor side effe…

This study is checking the long-term safety and effectiveness of a long-acting injectable drug called cabotegravir (CAB LA) for preventing HIV. It includes about 3,500 people who already received CAB LA in earlier HIV prevention studies. Participants will continue getting the sho…

This study compares two ways of providing HIV prevention medication, hepatitis C treatment, and substance use disorder care through telehealth to 350 people who inject drugs. Participants must be HIV-negative and have exchanged syringes recently. The goal is to see which approach…

This pilot study aims to reduce HIV, hepatitis C, and overdose risks among people who inject drugs in Baltimore. Researchers will identify high-risk locations and use peer-driven outreach to promote carrying naloxone and avoiding shared equipment. About 285 current drug users wil…

This study tests whether text messages can help prevent HIV in cisgender adolescent males (ages 13-22) who have sex with males. 5,000 participants across the US will receive either HIV prevention texts or general healthy lifestyle texts. The goal is to see if the messages reduce …

This study looks at two methods for people already taking PrEP (a daily pill to prevent HIV) to share HIV self-test kits and PrEP information with their friends and family. The goal is to see which method—directly giving out test kits or using referral codes—gets more people test…

This study aims to make HIV prevention easier for people in underserved communities in Rio de Janeiro, such as gay and bisexual men, transgender women, and sex workers. Instead of requiring visits to traditional clinics, the study offers HIV prevention pills (PrEP) directly in co…

This study tests a smartphone app called MY-RIDE designed to help homeless youth reduce substance use and adopt HIV prevention strategies like condom use and PrEP. Researchers will enroll 450 young people experiencing homelessness who use alcohol or drugs and are sexually active.…

This study tests a new way to prevent HIV among people who inject drugs and their friends. Researchers will train some participants to become peer educators, teaching their social network about HIV testing, PrEP (a daily pill that prevents HIV), and treatment for opioid use. The …

This study is testing a virtual reality tool designed to help young people who have experienced trauma reduce their risk of substance use and HIV. The study includes 50 participants, such as young men who have sex with men and adolescents with substance use disorder, aged 15 to 3…

This study tests a program that teaches Black male caregivers how to talk to and support the Black girls in their lives to reduce their risk of HIV, other sexually transmitted infections, and sexual violence. About 612 pairs of caregivers and girls aged 14-18 will take part. The …

This study tests a six-session program called SER Familia for Latino immigrant families with a parent and a child aged 12-17. The program, led by community health workers, aims to reduce stress from adapting to a new culture and build resilience to prevent substance abuse, intima…

This study tests whether taking the antibiotic doxycycline shortly after sex (called doxy-PEP) can prevent bacterial STIs like syphilis, gonorrhea, and chlamydia. It involves 200 sexual and gender minorities in Rio de Janeiro who are living with HIV or taking PrEP. Participants c…

This study is testing a program called TENDAI4PrEP to help pregnant women in Zimbabwe take PrEP, a daily pill that prevents HIV. The program combines problem-solving support to address barriers like depression and anxiety. About 132 pregnant women at risk for HIV will participate…

This study follows 3,000 people in the US who choose lenacapavir (a long-acting injection) to prevent HIV. Researchers want to see how well participants stick with the treatment over a year. The goal is to understand how this new PrEP option works in everyday clinics, not just in…

This study tests a culturally adapted form of cognitive behavioral therapy (CBT) for people living with HIV who also have depression and anxiety. Fifty adults in Peshawar, Pakistan will either receive six therapy sessions from trained health workers or standard care. The main goa…

This study looks back at medical records of 50 adults in France who were diagnosed with HIV between 2021 and 2024. Researchers want to find out if doctors missed signs of HIV during regular visits in the year before diagnosis. The goal is to understand why testing didn't happen a…

This study looks at how HIV affects a natural cell cleanup process called autophagy, which helps keep cells healthy. Researchers will compare HIV patients on different treatment schedules and healthy volunteers to see if this process is broken. The goal is to better understand wh…

This study aims to find out how common chronic kidney disease (CKD) is in semi-rural Sub-Saharan Africa and what factors increase the risk. Researchers will follow 1,200 adults for one year, measuring kidney function and checking for conditions like diabetes, high blood pressure,…

This study looks at 120 people with HIV who switch from daily oral pills to a long-acting injectable treatment. Researchers want to see if the injectable reduces inflammation and improves gut health better than pills. The goal is to understand how different treatments affect the …

This study follows 300 young men who have sex with men (ages 18-24) living with HIV in Ho Chi Minh City, Vietnam, for 12 months. Researchers will track how well they stick to their HIV medication, their viral suppression, and their mental health. The goal is to learn what helps o…

This study looks at how exercise changes blood pressure and heart rate control in people with HIV. Researchers will compare a group that exercises for 12 weeks to a group that does not. A healthy group will also be included for comparison. The goal is to understand if exercise ca…

This study looks at 400 women with HIV to understand how the balance of bacteria in the gut and vagina might make them more likely to get HPV and develop cervical lesions. Researchers will collect samples to track HPV infections and cervical changes over time. The goal is to lear…

This study looks at whether fungi moving from the gut into the blood can cause inflammation and worsen lung function in people with HIV. Researchers will measure fungal markers and lung health in 100 participants over time. The goal is to better understand why some people with HI…

This study looks at whether high-intensity exercise can help older adults with HIV improve their thinking and memory, and make exercise a lasting habit. Researchers will enroll 110 sedentary people with HIV who report fatigue. Participants will join a supervised exercise program …

This study tests a new approach called ACCESS to help syringe service programs offer routine HIV and Hepatitis C testing to people who inject drugs. The goal is to see if providing funding and support helps these programs test more people and connect them to care. About 40 progra…

This study looks at the gut bacteria of people with HIV who are 55 or older and have had the virus under control for at least 5 years. Researchers want to see if changes in gut bacteria over time are linked to signs of frailty and other health problems. The goal is to better unde…

This study looks at whether older adults (60+) with HIV have more trouble exercising due to how their leg muscles use energy. Researchers will compare people with and without HIV using MRI scans and walking tests. The goal is to understand the link between HIV, muscle metabolism,…

This study is testing whether an AI-powered chatbot on a smartphone can encourage more men in Malaysia to get tested for HIV. The study will enroll 296 men who have sex with men and have not been tested recently. Participants will use the chatbot and report if they get tested ove…

This study tracks 20 adults with chronic hepatitis delta (a serious liver infection) who are starting a new drug called bulevirtide. Researchers want to see how the drug changes the gut's bacteria and bile acids over 48 weeks, and how those changes relate to inflammation and live…

This early-stage study is testing a long-acting HIV drug called cabotegravir in 214 healthy adults. The goal is to see how the drug moves through the body and if it is safe when given as a shot. Participants do not have HIV and will not receive any direct treatment benefit, but t…